CWP232228, a highly potent selective Wnt/β-catenin signaling inhibitor, antagonizes binding of β-catenin to T-cell factor (TCF) in the nucleus. CWP232228 suppresses tumor formation and metastasis without toxicity through the inhibition of the growth of breast and liver cancer stem cells (CSCs) In Vitro CWP232228 (0.01-100 μM; 48 hours) inhibits cell proliferation with IC 50 values are 2 and 0.8 μM in mouse (4T1) and human (MDA-MB-435) breast cancer cell lines, respectively. CWP232228 (0.01-10 μM; 48 hours) inhibits cell proliferation with IC 50 s of 2.566, 2.630, and 2.596 μM in Hep3B, Huh7 and HepG2 cells, respectively. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Proliferation AssayCell Line: Mouse (4T1) and human (MDA-MB-435) breast cancer cell lines Concentration: 0.01, 0.1, 1, 10, 100 μM Incubation Time: 48 hours Result: IC 50 s were 2 and 0.8 μM for 4T1 and MDA-MB-435 cell lines, respectively. Cell Proliferation AssayCell Line: Hepatocellular carcinoma cell lines HepG2, Huh7, and Hep3B Concentration: 0.01, 0.1, 0.5, 1, 5, 10 μM Incubation Time: 48 hours Result: IC 50 s were 2.566, 2.630, and 2.596 μM for Hep3B, Huh7 and HepG2 cells, respectively. In Vivo CWP232228 (100 mg/kg, administered i.p.; daily; 21days for mice bearing 4T1 cell tumors; 60 days for mice bearing MDA-MB-435 cell tumors) results in a significant reduction in tumor volume . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: 7-week-old female Balb/c and NOD/SCID mice bearing 4T1 or MDA-MB-435 cell tumors Dosage: 100 mg/kg Administration: Administered i.p.; daily; 21days for mice bearing 4T1 cell tumors, 60 days for mice bearing MDA-MB-435 cell tumors Result: Treatment resulted in a significant reduction in tumor volume. Form:Solid IC50& Target:Wnt/β-catenin